Adverum Biotechnologies/ADVM

$2.00

2.56%
-
1D1W1MYTD1YMAX

About Adverum Biotechnologies

Adverum Biotechnologies, Inc. is a clinical-stage gene therapy company. The Company discovers and develops gene therapy product candidates that provides durable efficacy by inducing sustained expression of a therapeutic protein for ocular diseases. Its lead product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable levels of aflibercept associated with a sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) IVT injections. Ixo-vec is being developed for the treatment of patients with wet age-related macular degeneration (wet AMD) who are responsive to anti-VEGF therapy. Its second product candidate, ADVM-062 (AAV.7m8-L-opsin), is a gene therapy product candidate being developed to treat patients suffering from blue cone monochromacy (BCM) via a single IVT injection.

Ticker

ADVM

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Laurent Fischer

Employees

123

Headquarters

Redwood city, United States

ADVM Metrics

BasicAdvanced
$413.05M
Market cap
-
P/E ratio
-$1.26
EPS
0.87
Beta
-
Dividend rate

What the Analysts think about ADVM

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
110% upside
High $6.00
Low $3.00
$2.00
Current price
$4.20
Average price target

ADVM Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-32.8M
4.13%
Profit margin
0%
-

ADVM Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 4.71%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.33
-$0.29
-$0.31
-$0.33
-
Expected
-$0.36
-$0.32
-$0.33
-$0.32
-$0.34
Surprise
-8.94%
-9.49%
-5.72%
4.71%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Adverum Biotechnologies stock

Buy or sell Adverum Biotechnologies stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing